Sentiment Summary
Recent Events
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
Quarterly dividend of $0.85 per share has an ex-dividend date of June 15, 2026, scheduled.
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
The company presented positive Phase III trial data for its 'Defu Combination' (Anlotinib plus Bemotuzumab) as a first-line treatment for non-squamous non-small cell lung cancer (nsq-NSCLC) at the 2026 ASCO meeting, showing a significant 6-month improvement in median Progression-Free Survival (mPFS) compared to the control group.
The company granted a total of 14,736,658 restricted share units to four directors, the rotating CEO, certain employees, and a service provider on June 4, 2026.
Gilead announced the successful completion of the acquisition of Ouro Medicines on 2026-06-04, adding gamgertamig to its inflammation pipeline; Medium importance estimated as it strengthens the portfolio, expected.
Announced repurchase of 812,400 H-shares for approximately HK$101 million on June 4, 2026, as part of an ongoing share buyback program; low importance as the buyback is routine and likely to result in >=1% price impact.
The company announced on June 4, 2026, that it had repurchased 34,000 of its own shares for approximately HK$6.46 million. Low importance estimated due to the relatively small buyback size compared to market capitalization; scheduled.
Announced a long-dated, CHF-denominated senior notes issuance on 2026-06-04.
The New Drug Application (NDA) for Olipudase (奥莱泊肽), a GLP-1/GIP dual receptor agonist, was accepted for review by China's NMPA on June 3, 2026. Analysts estimate a >10% price impact due to the drug's significant market potential expected.
The company announced positive interim data from a Phase II study of Ivonescimab for first-line metastatic colorectal cancer (mCRC) at ASCO 2026, showing a 70.8% objective response rate and 100% disease control rate. Medium importance is estimated as Phase II data typically results in a 5-10% price impact scheduled.
Presented new Phase 3 data for UPLIZNA at the EULAR 2026 Congress, showing a 0% flare rate over one year in patients with IgG4-Related Disease who continued treatment. Medium importance as positive clinical data supports market share, expected.
Johnson & Johnson announced on June 3, 2026, that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for SLE; positive clinical data for a major pipeline candidate is estimated to have a 5-10% market impact, expected.
Announced on 2026-06-03 plans to halve its €2.3 billion investment in a new German plant; medium impact estimated due to regulatory headwinds and reduced growth capacity, expected.
Associate company Legend Biotech announced on June 2, 2026, positive preliminary clinical data for its in vivo CAR-T cell therapy, LB2501, for non-Hodgkin lymphoma, leading to a significant stock price increase.
On June 2, 2026, the company announced updated data for mesutoclax in MDS and AML at ASCO 2026 showing high efficacy; high impact due to clinical success expected.
Bristol Myers Squibb and partner SystImmune announced on 2026-06-02 that their ADC iza-bren showed significant Phase 3 results in TNBC and ESCC. This major clinical success is estimated to have a >10% price impact expected.
Kelun-Biotech announced positive first-in-human study results for its novel B7-H3 ADC drug, SKB500, at the 2026 ASCO annual meeting on June 2, 2026. The data showed broad-spectrum antitumor activity across multiple solid tumors, with notable efficacy in small cell lung cancer (SCLC).
The European Commission approved AQUIPTA (atogepant) for the acute treatment of migraine in adults on 2026-06-02; analysts forecast this market expansion will result in a price impact of ≥5% expected.
Announced positive results from the Phase 3 IDEAL study for Livdelzi on 2026-06-02; Medium importance estimated due to high probability of future approval, expected.
Akeso announced that its drug Ivonescimab plus chemotherapy showed a 34% reduction in the risk of death in the Phase III HARMONi-6 trial for first-line advanced squamous non-small cell lung cancer. The landmark results were presented at the ASCO 2026 Plenary Session and published in The Lancet. High importance is estimated due to the significant clinical success in a major indication, likely resulting in >10% price impact scheduled.
European Commission granted marketing authorization for IMDYLLTRA (tarlatamab) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. High importance due to major drug approval potential, expected.
The U.S. FDA accepted Vertex's Biologics License Application (BLA) for povetacicept for the treatment of IgA nephropathy (IgAN) on June 1, 2026, granting it priority review. High importance is estimated due to the potential for >10% valuation impact from this major pipeline asset, with a PDUFA date of November 30, 2026, expected.
Presentation of positive long-term follow-up data for IBI363 (PD-1/IL-2) at the 2026 ASCO annual meeting; 5-10% price impact estimated due to clinical data validation scheduled
Provided a business update on June 1, 2026, maintaining full-year 2026 revenue growth guidance of 13-17% and reporting 69 new projects; medium importance reflects an estimated price impact of 5% or more.
Announced on June 1, 2026, that the Phase 3 LITESPARK-012 study of a Keytruda-based triplet therapy in first-line advanced clear cell renal cell carcinoma (RCC) did not meet its primary endpoints.
Ex-dividend date on June 1, 2026, for a final dividend of RMB 0.5390 and a special dividend of RMB 0.6714. Low importance estimated as dividend payouts typically result in minor price adjustments; scheduled.
The U.S. FDA accepted for Priority Review the sNDA for Camzyos on 2026-06-01. This regulatory milestone is estimated to have a >1% price impact expected.
The company announced on May 31, 2026, that its Phase III study (OptiTROP-Lung05) of sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab for first-line treatment of PD-L1 positive NSCLC met its primary endpoint.
On May 31, 2026, Johnson & Johnson announced positive final results from the Phase 3 PROTEUS study of ERLEADA in prostate cancer; successful Phase 3 results for an oncology blockbuster typically drive a 5-10% price impact, expected.
Pfizer announced positive Phase 3 TALAPRO-3 trial results on 2026-05-30 for Talzenna plus Xtandi; Medium importance estimated due to significant reduction in disease progression risk.
Announcement of strategic global licensing agreement with Pfizer for 12 cancer medicines ($10.5B total value); >10% price impact estimated due to massive deal size expected
Announced positive Phase 3 SUCCESSOR-2 trial results on 2026-05-29 showing a 52% reduction in disease progression risk for multiple myeloma. This breakthrough is estimated to have a >10% price impact expected.
The company announced positive pivotal data from two Phase III clinical trials (B-Well 1 and B-Well 2) for bepirovirsen for the treatment of chronic hepatitis B, which were presented at the 2026 European Association for the Study of the Liver (EASL) Congress and published in the New England Journal of Medicine.
RemeGen's shares were included in the MSCI China Index, effective after market close on May 29, 2026. Analysts estimate this will drive institutional demand with a price impact of at least 5%, estimated.
Received FDA Breakthrough Therapy designation for calderasib (MK-1084) on May 29, 2026. Medium importance as this designation accelerates the development of a key oncology candidate.
Pfizer presented seven-year CROWN trial analysis for LORBRENA on 2026-05-29; Medium importance estimated as long-term survival data strengthens its competitive position.
Announced on May 29, 2026, that a trustee purchased approximately 5.7 million shares on the open market between May 19 and May 29 for the company's share award scheme.
Ex-dividend date on May 29, 2026, for a final dividend of CNY 1.57927 per share for the year 2025; low importance as the price adjustment is expected to be >=1%.